2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123025
    Schizozygine 2047-63-4 98%
    Schizozygine is an alkaloid that can be isolated from Schizozygia caffaeoides. Schizozygia caffaeoides has been used as a traditional medicine for skin disease. The leaf extracts has high antifungal and antimicrobial activity.
    Schizozygine
  • HY-123095
    TS 155-2 1314486-37-7 98%
    TS 155-2 (JBIR 100), an antimicrobial agent, is a Bafilomycin analogue and an antibiotic. TS 155-2 can be isolated from a culture of Streptomyces sp. TS 155-2 inhibits V-ATPase activity. V-ATPase is correlated with an increasing number of diseases such as osteopetrosis, male infertility and renal acidosis.
    TS 155-2
  • HY-123103
    Linetastine 159776-68-8 98%
    Linetastine is an orally active and potent 5-Lipoxygenase inhibitor. Linetastine shows antihistamine activity. Linetastine inhibits leukotriene production and antagonizes the effect of histamine. Linetastine inhibits the release of leukotrienes B4 and C4 from calcium ionophore-stimulated human leukocytes.
    Linetastine
  • HY-123117
    VA5 2088001-24-3 98%
    VA5 is a BTK kinaseinhibitor. VA5 has the potential to be used to study diseases associated with BTK kinase activity.
    VA5
  • HY-123121
    Nargenicin A1 70695-02-2 98%
    Nargenicin A1 is an antibiotic agent against various Gram-positive bacteria. Nargenicin A1 shows anti-inflammatory activity. Nargenicin A1 protects HINAE cells against Tacrolimus (HY-13756)-induced DNA damage and apoptosis. Nargenicin A1 can also be used for the research of acute myeloid leukemia.
    Nargenicin A1
  • HY-123164
    IVL 745 229627-58-1 98%
    IVL 745 (XRP 1745A) is a very late antigen 4 (VLA-4, integrin α4β1) antagonist. IVL 745 reduces the airway inflammatory response of sensitized rats and sheep. IVL 745 can be used for airway inflammation and asthma research.
    IVL 745
  • HY-123206
    R-96544 free base 167144-79-8 98%
    R-96544 (free base) is a potent, selective and competitive 5-HT2 receptor antagonist. R-96544 (free base) inhibits platelet aggregation induced by serotonin, and inhibits 5-HT2A receptor-mediated contraction of guinea pig trachea.
    R-96544 free base
  • HY-123208
    Sulfonterol 42461-79-0 98%
    Sulfonterol is a benzenemethanol derivative. Sulfonterol is a Bronchodilator.
    Sulfonterol
  • HY-123220
    S 1592 25552-58-3 98%
    S 1592 is a compound that possesses bronchodilating and antianaphylactic properties and does not affect gastrointestinal propulsion.
    S 1592
  • HY-123221
    RS-0481 134931-74-1 98%
    RS-0481 is an orally active lymphocyte population function restorer. RS-0481 enhances IL-2 production activity. RS-0481 can re-establish the function of certain lymphoid cell populations impaired by the presence of a growing tumor in an animal. RS-0481 markedly augments the tumor-specific cytotoxic T lymphocytes, TDTH, and the nonspecific lymphokine-activated-killer-cell-like cell responses.
    RS-0481
  • HY-123342
    Cinmetacin 20168-99-4 98%
    Cinmetacin is an orally active and selective anti-inflammatory agent targeting cyclooxygenase (COX). Cinmetacin is promising for research of inflammatory diseases (e.g., arthritis).
    Cinmetacin
  • HY-123382
    GSK-1482160 (isomer) 1695551-19-9 98%
    GSK-1482160 isomer is the isomer of GSK-1482160 (HY-19888). GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC50s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI).
    GSK-1482160 (isomer)
  • HY-123399
    Ro 19-1400 122937-55-7 98%
    Ro 19-1400 is a platelet-activating factor antagonist that directly inhibits immunoglobulin E-dependent mediator release.
    Ro 19-1400
  • HY-123432
    AHR-13268D 130838-11-8 98%
    AHR-13268D is an oral active antiallergic and antihistaminic agent, with bioavailable approximately 88%. AHR-13268D is a potent inhibitor of histamine release from rat peritoneal mast cells, with the IC50 of 0.51 nM.
    AHR-13268D
  • HY-123447
    GR-175737 176860-26-7 98%
    GR 175737 is a partial histamine H3 receptor agonist, with an EC50 of 7.8 nM. GR 175737 can be used in the research of inflammatory diseases.
    GR-175737
  • HY-123461
    Sul-121 hydrochloride 1541170-25-5 98%
    Sul-121 hydrochloride is a novel compound with anti-oxidative capacity that effectively inhibits airway inflammation and hyperresponsiveness (AHR) in experimental models of chronic obstructive pulmonary disease (COPD). Sul-121 hydrochloride prevents lipopolysaccharide-induced airway neutrophilia and AHR in a dose-dependent manner. Sul-121 hydrochloride also demonstrates the ability to reduce oxidative stress markers in human airway smooth muscle cells. Sul-121 hydrochloride inhibits nuclear translocation of the NF-κB subunit, p65, thereby diminishing pro-inflammatory cytokine release.
    Sul-121 hydrochloride
  • HY-123493
    P552-02 mesylate 587879-54-7 98%
    P552-02 (552-02) mesylate is a sodium channel blocker that is potentially used for the treatment of cystic fibrosis, exhibiting biological activity that enhances mucociliary clearance in the lungs while minimizing the risk of hyperkalaemia.
    P552-02 mesylate
  • HY-123522
    PAT-048 1359983-15-5 98%
    PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo.
    PAT-048
  • HY-123531
    JNJ 10329670 400797-24-2 98%
    JNJ 10329670 is a potent and selective noncovalent cathepsin S inhibitor with a Ki value of 34 nM for human cathepsin S. JNJ 10329670 blocks invariant chain proteolysis in B cells and dendritic cells, as well as antigen-induced T cell proliferation.
    JNJ 10329670
  • HY-123550
    Rosenonolactone 508-71-4 98%
    Rosenonolactone shows inhibitory activity against prolyl endopeptidase and thrombin and cholesterol ester transfer protein.
    Rosenonolactone
Cat. No. Product Name / Synonyms Application Reactivity